1. Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and safety
of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169 (6) …

[Treatment of Alzheimer's disease: status quo and future considerations]. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …

The AD2000 study was a randomized placebo-controlled trial, the effects of donepezil, a
cholinesterase inhibitor, in patients with Alzheimer's disease. It was the first long-term RCT …

Donepezil is the most widely used acetylcholinesterase inhibitor licensed for symptomatic
treatment of mild-to-moderate Alzheimer's disease. Clinical placebo-controlled trials and …

Background Cholinesterase inhibitors, which are now the recommended treatment for
patients with mild to moderate Alzheimer's Disease have been in use since the late 1990's …

Background: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most
clinicians would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to …

A systematic review of 22 clinical trials involving cholinesterase inhibitors for the treatment of
Alzheimer's disease was recently conducted in Germany by Kaduszkiewicz and colleagues …

Background There have been very limited investigations of cholinesterase inhibitor therapy
in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil …

This multicenter open-label clinical trial was designed to investigate the safety and efficacy
of donepezil, a selective acetylcholinesterase inhibitor, in the treatment of Alzheimer's …

Objective: To systematically review published clinical trials of the pharmacotherapy of
Alzheimer disease (AD). Method: We searched MEDLINE for published English-language …